Date: 2017-10-19
Type of information: Production agreement
Compound: cancer vaccines based on DCPrime’s technology platform DCOne®
Company: apceth (Germany) DCPrime (The Netherlands)
Therapeutic area: Cancer - Oncology
Type agreement: manufacturing - production
Action mechanism:
- immunotherapy product. The DCOne® cell line is derived from myeloid leukemia cells and expresses a number of validated tumor antigens. This makes the platform suitable for application in patients with myeloid and other hematological cancers. In addition, DCOne® cells can be
loaded with tumor associated antigens of choice, to develop cancer-specific vaccine formulations for multiple other (solid) cancer types. DCP-001 is positioned as a consolidation vaccine therapy in acute myeloid leukemia. A Phase
I/IIa study with this product has been completed and shows that DCP-001 is a safe product that induces a clear anti-tumor response in patients, and strong survival improvement in
several of the studied patients. DCPrime received orphan drug designation in AML for this product from the EMA and is currently preparing a multi-center Phase II trial to
demonstrate efficacy in AML patients.
Disease:
Details:
- • On October 19, 2017, DCPrime, a clinical
stage company developing dendritic cell vaccines to treat cancer, and apceth Biopharma, an established contract manufacturing organization in the field of gene and cell
therapy, reported that they have entered into a strategic manufacturing agreement. The collaboration involves clinical batch production and the development of a commercial scale
manufacturing process of cancer vaccines based on DCPrime’s technology platform DCOne®.
- The companies also announce that apceth has recently successfully passed an inspection by the District Government of Upper Bavaria and the Paul-Ehrlich-Institute for the
manufacturing license for production of DCP-001, DCPrime’s lead program. This will enable DCPrime to enter into a Phase II Proof of Concept study in Acute Myeloid Leukemia.
Financial terms:
Latest news:
Is general: Yes
